Search - tctmd.com

Displaying 521 - 540 of 1332

Sort: Relevancy | Date

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

News Daily News

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Michael O'Riordan

March 26, 2020

News Daily News

Cardiac Injury in COVID-19 Sharply Increases Risk of Death

March 26, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

News Daily News

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

Yael L. Maxwell

March 10, 2020

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

News Daily News

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

Yael L. Maxwell

March 06, 2020

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

March 02, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

News Conference News CRT 2020

Meta-analysis Upholds Complete PCI in STEMI, as Thoughts Turn to Timing, Costs

Michael O'Riordan

February 24, 2020

ACS After TAVR a Unique Condition With Poor Prognosis

News Daily News

ACS After TAVR a Unique Condition With Poor Prognosis

February 05, 2020

CCTA to Avoid Invasive Cath in NSTE ACS? Clues From VERDICT

News Daily News

CCTA to Avoid Invasive Cath in NSTE ACS? Clues From VERDICT

February 03, 2020

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

News Daily News

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Michael O'Riordan

January 27, 2020

‘Super-Dense’ Calcified Plaque Appears Protective Against ACS

News Daily News

‘Super-Dense’ Calcified Plaque Appears Protective Against ACS

Michael O'Riordan

January 24, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

January 20, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

hs-Troponin Fails to ID Ischemia in Symptomatic Stable CAD

News Daily News

hs-Troponin Fails to ID Ischemia in Symptomatic Stable CAD

January 10, 2020

For Real-world ACS Patients, FFR Use in PCI Tied to Lower In-Hospital Mortality

News Daily News

For Real-world ACS Patients, FFR Use in PCI Tied to Lower In-Hospital Mortality

Michael O'Riordan

December 05, 2019

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

News Daily News

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

Michael O'Riordan

November 29, 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

November 21, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.